Evidence map›Paper›PMID 24636783›Full record

ArticleMedical hypotheses2014

Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Kenneth Blum, Marlene Oscar-Berman, Rajendra D Badgaiyan, Tomas Palomo, Mark S Gold

Open access · greenAbstract read
In one paragraph

Article in Medical hypotheses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Kenneth BlumDepartment of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA; Department of Clinical Neurology, Path Research Foundation, New York, NY, USA; Department of Genomics, IGENE, LLC, Austin, TX, USA; Department of Psychiatry, Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT, USA; Dominion Diagnostics, LLC, North Kingstown, RI, USA; Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach, CA, USA; RD Solutions, LLC, Research Center, Austin, TX, USA; Department of Nutrigenomics, RD Solutions, LLC, La Jolla, CA, USA. Electronic address: drd2gene@gmail.com.
Marlene Oscar-BermanDepartments of Psychiatry and Anatomy & Neurobiology, Boston University School of Medicine and Boston VA Healthcare System, Boston, MA, USA.
Rajendra D BadgaiyanDepartment of Psychiatry and Neuroimaging Laboratory, SUNY-at Buffalo, Buffalo, NY, USA.
Tomas PalomoUnidad de Alcoholismo y Patología Dual, Servicio de Psiquiatría, Hospital Universitario 12 de Octubre, Av. de Córdoba s/n, Madrid E-28041, Spain.
Mark S GoldDepartment of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA.
Florida College · USUniversity at Buffalo, State University of New York · USUniversity of Florida · USVA Boston Healthcare System · US

Funding

AFFECTIVE AND CONATIVE CHANGES IN ALCOHOLISMR01AA007112 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERMAN, MARLENE OSCAR · 1987 to 2019
$8.3M
Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
AFFECTIVE AND CONATIVE CHANGES IN ALCOHOLISMK05AA000219 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERMAN, MARLENE OSCAR · 1997 to 2011
$1.8M
Detection of Dopamine Release During a Cognitive TaskR21MH073624 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI BADGAIYAN, RAJENDRA D · 2005 to 2006
$368k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479NIAAA NIH HHS K05 AA000219NIAAA NIH HHS K05-AA00219NIAAA NIH HHS R01 AA007112NIAAA NIH HHS R01-AA07112NIMH NIH HHS 1R21MH073624NIMH NIH HHS R21 MH073624NINDS NIH HHS 1R01NS073884NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

The dopamine system has been implicated in both substance use disorder (SUD) and schizophrenia. A recent meta-analysis suggests that A1 allele of the DRD2 gene imposes genetic risk for SUD, especially alcoholism and has been implicated in Reward Deficiency Syndrome (RDS). We hypothesize that dopamine D2 receptor (DRD2) gene Taq1 A2 allele is associated with a subtype of non-SUD schizophrenics and as such may act as a putative protective agent against the development of addiction to alcohol or other drugs of abuse. Schizophrenics with SUD may be carriers of the DRD2 Taq1 A1 allele, and/or other RDS reward polymorphisms and have hypodopaminergic reward function. One plausible mechanism for alcohol seeking in schizophrenics with SUD, based on previous research, may be a deficiency of gamma type endorphins that has been linked to schizophrenic type psychosis. We also propose that alcohol seeking behavior in schizophrenics, may serve as a physiological self-healing process linked to the increased function of the gamma endorphins, thereby reducing abnormal dopaminergic activity at the nucleus accumbens (NAc). These hypotheses warrant further investigation and cautious interpretation. We, therefore, encourage research involving neuroimaging, genome wide association studies (GWAS), and epigenetic investigation into the relationship between neurogenetics and systems biology to unravel the role of dopamine in psychiatric illness and SUD.

Indexed as

DopamineHumansModels, TheoreticalSchizophreniaSubstance-Related DisordersDopamine

Identifiers

PMID24636783
PMCPMC4039414
OpenAlexW1986911908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.